Gillespie et al.[18] reviewed BM incidence across NSCLC genotypes, reporting an overall rate of 28.6% (95% CI 26.1–31.0), with the highest rates observed in ALK‐positive (34.9%) and RET‐rearranged (32.2%) tumors. This evidence concerns the gene ALK and non-small cell lung carcinoma.